Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
20
DAWN Quote, Financials, Valuation and Earnings
Last price:
$10.03
Seasonality move
:
-34.56%
Day range:
$10.11 - $10.62
52-week range:
$5.64 - $13.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.75x
P/B ratio:
2.41x
Volume:
1.4M
Avg. volume:
2.4M
1-year change:
14.46%
Market cap:
$1.1B
Revenue:
$158.2M
EPS (TTM):
-$1.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$49.8M | -$0.15 | 79.18% | -57.2% | $22.75 |
|
ATEC
Alphatec Holdings, Inc.
|
$212.2M | $0.04 | 17.11% | -88.21% | $24.62 |
|
GMED
Globus Medical, Inc.
|
$803.3M | $1.15 | 23.66% | 68.87% | $109.54 |
|
IRTC
iRhythm Holdings, Inc.
|
$202.6M | $0.06 | 22.27% | -37.14% | $212.87 |
|
PRCT
PROCEPT BioRobotics Corp.
|
$93.7M | -$0.32 | 16.65% | -23.05% | $32.00 |
|
TMDX
TransMedics Group, Inc.
|
$155.3M | $0.37 | 21.06% | -6.01% | $157.55 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$10.37 | $22.75 | $1.1B | -- | $0.00 | 0% | 6.75x |
|
ATEC
Alphatec Holdings, Inc.
|
$13.47 | $24.62 | $2B | -- | $0.00 | 0% | 2.64x |
|
GMED
Globus Medical, Inc.
|
$93.80 | $109.54 | $12.6B | 23.84x | $0.00 | 0% | 4.37x |
|
IRTC
iRhythm Holdings, Inc.
|
$128.46 | $212.87 | $4.2B | -- | $0.00 | 0% | 5.55x |
|
PRCT
PROCEPT BioRobotics Corp.
|
$25.90 | $32.00 | $1.4B | -- | $0.00 | 0% | 4.67x |
|
TMDX
TransMedics Group, Inc.
|
$147.00 | $157.55 | $5B | 30.27x | $0.00 | 0% | 9.84x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
0.63% | -0.042 | 0.29% | 7.73x |
|
ATEC
Alphatec Holdings, Inc.
|
94.3% | 1.734 | 18.93% | 1.24x |
|
GMED
Globus Medical, Inc.
|
2.55% | -0.866 | 1.02% | 2.55x |
|
IRTC
iRhythm Holdings, Inc.
|
82.72% | 2.574 | 12.76% | 4.44x |
|
PRCT
PROCEPT BioRobotics Corp.
|
17.66% | 1.070 | 4.46% | 5.64x |
|
TMDX
TransMedics Group, Inc.
|
52.33% | 1.960 | 12.49% | 6.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$47.6M | -$27.5M | -22.84% | -22.98% | -51.12% | -$14.1M |
|
ATEC
Alphatec Holdings, Inc.
|
$130.4M | -$5.4M | -23.65% | -1092.5% | -2.52% | $5.7M |
|
GMED
Globus Medical, Inc.
|
$536M | $181.6M | 11.94% | 12.49% | 21.98% | $202.3M |
|
IRTC
iRhythm Holdings, Inc.
|
$148.1M | $8.8M | -5.27% | -40.07% | 4.2% | $14.5M |
|
PRCT
PROCEPT BioRobotics Corp.
|
$46.3M | -$31M | -20.6% | -24.85% | -40.64% | -$12.2M |
|
TMDX
TransMedics Group, Inc.
|
$93.4M | $21.3M | 22.46% | 57.97% | 13.23% | $19M |
Day One Biopharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns DAWN or ATEC?
Alphatec Holdings, Inc. has a net margin of -39.61% compared to Day One Biopharmaceuticals, Inc.'s net margin of -10.21%. Day One Biopharmaceuticals, Inc.'s return on equity of -22.98% beat Alphatec Holdings, Inc.'s return on equity of -1092.5%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.68% -$0.21 $444M ATECAlphatec Holdings, Inc.61.24% -$0.14 $632.1M -
What do Analysts Say About DAWN or ATEC?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.75, signalling upside risk potential of 119.38%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 82.74%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than Alphatec Holdings, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than Alphatec Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 ATECAlphatec Holdings, Inc.8 1 0 -
Is DAWN or ATEC More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.020, suggesting its more volatile than the S&P 500 by 1.994%.
-
Which is a Better Dividend Stock DAWN or ATEC?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or ATEC?
Day One Biopharmaceuticals, Inc. quarterly revenues are $53.7M, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $212.9M. Day One Biopharmaceuticals, Inc.'s net income of -$21.3M is higher than Alphatec Holdings, Inc.'s net income of -$21.7M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 6.75x versus 2.64x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.6.75x -- $53.7M -$21.3M ATECAlphatec Holdings, Inc.2.64x -- $212.9M -$21.7M
-
Which has Higher Returns DAWN or GMED?
Globus Medical, Inc. has a net margin of -39.61% compared to Day One Biopharmaceuticals, Inc.'s net margin of 17.01%. Day One Biopharmaceuticals, Inc.'s return on equity of -22.98% beat Globus Medical, Inc.'s return on equity of 12.49%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.68% -$0.21 $444M GMEDGlobus Medical, Inc.64.85% $1.03 $4.7B -
What do Analysts Say About DAWN or GMED?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.75, signalling upside risk potential of 119.38%. On the other hand Globus Medical, Inc. has an analysts' consensus of $109.54 which suggests that it could grow by 16.78%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than Globus Medical, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than Globus Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 GMEDGlobus Medical, Inc.6 4 0 -
Is DAWN or GMED More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.048, suggesting its more volatile than the S&P 500 by 4.758%.
-
Which is a Better Dividend Stock DAWN or GMED?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or GMED?
Day One Biopharmaceuticals, Inc. quarterly revenues are $53.7M, which are smaller than Globus Medical, Inc. quarterly revenues of $826.4M. Day One Biopharmaceuticals, Inc.'s net income of -$21.3M is lower than Globus Medical, Inc.'s net income of $140.6M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while Globus Medical, Inc.'s PE ratio is 23.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 6.75x versus 4.37x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.6.75x -- $53.7M -$21.3M GMEDGlobus Medical, Inc.4.37x 23.84x $826.4M $140.6M
-
Which has Higher Returns DAWN or IRTC?
iRhythm Holdings, Inc. has a net margin of -39.61% compared to Day One Biopharmaceuticals, Inc.'s net margin of 2.67%. Day One Biopharmaceuticals, Inc.'s return on equity of -22.98% beat iRhythm Holdings, Inc.'s return on equity of -40.07%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.68% -$0.21 $444M IRTCiRhythm Holdings, Inc.70.88% $0.17 $883.9M -
What do Analysts Say About DAWN or IRTC?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.75, signalling upside risk potential of 119.38%. On the other hand iRhythm Holdings, Inc. has an analysts' consensus of $212.87 which suggests that it could grow by 65.71%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than iRhythm Holdings, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than iRhythm Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 IRTCiRhythm Holdings, Inc.12 1 0 -
Is DAWN or IRTC More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iRhythm Holdings, Inc. has a beta of 1.095, suggesting its more volatile than the S&P 500 by 9.462%.
-
Which is a Better Dividend Stock DAWN or IRTC?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. iRhythm Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or IRTC?
Day One Biopharmaceuticals, Inc. quarterly revenues are $53.7M, which are smaller than iRhythm Holdings, Inc. quarterly revenues of $208.9M. Day One Biopharmaceuticals, Inc.'s net income of -$21.3M is lower than iRhythm Holdings, Inc.'s net income of $5.6M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while iRhythm Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 6.75x versus 5.55x for iRhythm Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.6.75x -- $53.7M -$21.3M IRTCiRhythm Holdings, Inc.5.55x -- $208.9M $5.6M
-
Which has Higher Returns DAWN or PRCT?
PROCEPT BioRobotics Corp. has a net margin of -39.61% compared to Day One Biopharmaceuticals, Inc.'s net margin of -39.07%. Day One Biopharmaceuticals, Inc.'s return on equity of -22.98% beat PROCEPT BioRobotics Corp.'s return on equity of -24.85%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.68% -$0.21 $444M PRCTPROCEPT BioRobotics Corp.60.63% -$0.53 $444.4M -
What do Analysts Say About DAWN or PRCT?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.75, signalling upside risk potential of 119.38%. On the other hand PROCEPT BioRobotics Corp. has an analysts' consensus of $32.00 which suggests that it could grow by 23.55%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than PROCEPT BioRobotics Corp., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than PROCEPT BioRobotics Corp..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 PRCTPROCEPT BioRobotics Corp.6 3 0 -
Is DAWN or PRCT More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PROCEPT BioRobotics Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock DAWN or PRCT?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PROCEPT BioRobotics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. PROCEPT BioRobotics Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or PRCT?
Day One Biopharmaceuticals, Inc. quarterly revenues are $53.7M, which are smaller than PROCEPT BioRobotics Corp. quarterly revenues of $76.4M. Day One Biopharmaceuticals, Inc.'s net income of -$21.3M is higher than PROCEPT BioRobotics Corp.'s net income of -$29.8M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while PROCEPT BioRobotics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 6.75x versus 4.67x for PROCEPT BioRobotics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.6.75x -- $53.7M -$21.3M PRCTPROCEPT BioRobotics Corp.4.67x -- $76.4M -$29.8M
-
Which has Higher Returns DAWN or TMDX?
TransMedics Group, Inc. has a net margin of -39.61% compared to Day One Biopharmaceuticals, Inc.'s net margin of 65.55%. Day One Biopharmaceuticals, Inc.'s return on equity of -22.98% beat TransMedics Group, Inc.'s return on equity of 57.97%.
Company Gross Margin Earnings Per Share Invested Capital DAWNDay One Biopharmaceuticals, Inc.88.68% -$0.21 $444M TMDXTransMedics Group, Inc.58.11% $2.58 $992.4M -
What do Analysts Say About DAWN or TMDX?
Day One Biopharmaceuticals, Inc. has a consensus price target of $22.75, signalling upside risk potential of 119.38%. On the other hand TransMedics Group, Inc. has an analysts' consensus of $157.55 which suggests that it could grow by 7.17%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than TransMedics Group, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than TransMedics Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DAWNDay One Biopharmaceuticals, Inc.5 1 0 TMDXTransMedics Group, Inc.7 3 0 -
Is DAWN or TMDX More Risky?
Day One Biopharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison TransMedics Group, Inc. has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.923%.
-
Which is a Better Dividend Stock DAWN or TMDX?
Day One Biopharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Day One Biopharmaceuticals, Inc. pays -- of its earnings as a dividend. TransMedics Group, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DAWN or TMDX?
Day One Biopharmaceuticals, Inc. quarterly revenues are $53.7M, which are smaller than TransMedics Group, Inc. quarterly revenues of $160.8M. Day One Biopharmaceuticals, Inc.'s net income of -$21.3M is lower than TransMedics Group, Inc.'s net income of $105.4M. Notably, Day One Biopharmaceuticals, Inc.'s price-to-earnings ratio is -- while TransMedics Group, Inc.'s PE ratio is 30.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Day One Biopharmaceuticals, Inc. is 6.75x versus 9.84x for TransMedics Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DAWNDay One Biopharmaceuticals, Inc.6.75x -- $53.7M -$21.3M TMDXTransMedics Group, Inc.9.84x 30.27x $160.8M $105.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 9.65% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 6.93% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 0.87% over the past day.
